IBEX 35
10.909,30 +54,60 (+0,50%) Euro Stoxx 50
4.953,71 +32,23 (+0,65%) Dólar/Euro
1,0783 +0,0016 (+0,15%) Petróleo Brent
83,63 +0,67 (+0,81%) Oro
2.332,80 +24,20 (+1,05%) Bitcoin EUR
59.112,43 -275,97 (-0,46%)
Cantabio Pharmaceuticals, Inc. (CTBO)
Cantabio Pharmaceuticals, Inc.
2225 East Bayshore Road
Suite 200
Palo Alto, CA 94303
United States
844-200-2826
https://www.cantabio.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Gergely Toth | Founder, CEO, President & Director | 157k | N/A | 1974 |
| Dr. Thomas Roger Sawyer M.B.A., Ph.D. | CFO & Director | 109k | N/A | 1970 |
| Dr. Balász Herberth | Head of Cell Biology & In Vitro Pharmacology | N/A | N/A | N/A |
Descripción
Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.
Gobierno corporativo
El ISS Governance QualityScore de Cantabio Pharmaceuticals, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
